



Press Release

STRIDES ARCOLAB JOINS THE MALAYSIAN BIO-XCELL ECOSYSTEM

Strides Arcolab, through its subsidiary Agila Specialties (Malaysia) SDN BHD, is to establish a manufacturing plant in Malaysia's dedicated biotechnology park and ecosystem

Bangalore, 29 June 2011 – Agila Specialties (Malaysia) SDN BHD, the specialties subsidiary of leading Indian pharmaceutical manufacturer Strides Arcolab Ltd, and Malaysian Bio-XCell Sdn Bhd (Bio-XCell) today exchanged agreements for the establishment of a customized facility to manufacture biopharmaceuticals and sterile injectables in the Bio-XCell ecosystem in Johor, Malaysia.

The agreement was exchanged by, Mr Adam Levitt, CEO- Americas of Strides Arcolab Ltd, and Mr Raja Ridzwa Raja Abdul Aziz, CEO of Bio-XCell in the presence of The Right Hon. Tan Sri Muhyiddin Yassin, Deputy Prime Minister of Malaysia during the BIO International Convention 2011 in Washington DC.

At the conclusion of the signing Mr Adam Levitt said "We are happy to finalize this agreement and excited at what's ahead in Bio-XCell. Malaysia provides us with a strategic location to expand our manufacturing operations. The attractive financial incentives by the Malaysian government and the presence of a Pharma/Biotech ecosystem were the catalysts to our decision".

The project will be built by Bio-XCell to the design requirements of Strides and will be leased out to Strides on a long-term basis. The lease rentals are applicable from the date of commercialization which supports the biotech strategy of Strides where there is a long gestation period from development to commercialization

In the light of Agila's partnerships with global pharmaceutical corporations the establishment of a facility in Bio-XCell represents a strategic move to further bolster Agila's manufacturing presence in the region"

With a world class sterile injectables platform, robust product pipeline and record regulatory filings, hi-tech manufacturing capacities across countries, an impeccable record of quality and marquee customers and partners across the healthcare industry, Agila is poised to be a major anchor tenant for the Bio-XCell ecosystem.

The facility in Bio-XCell will join 8 world class Specialty manufacturing facilities under Strides Arcolab worldwide – including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world – in supplying finished products to its quality and marquee customers.

"We are very pleased to welcome Agila Specialties into the Bio-XCell ecosystem. The addition of Agila Specialties to the Bio-XCell ecosystem reflects the strong market acceptance Bio-XCell has earned since its launch in last year's BIO International Convention," YM Raja Ridzwa said.

Agila joins Biocon of India, Metabolic Explorer from France and Glycos Biotechnologies of the USA as the early entrants into the Bio-XCell ecosystem. The site is supported by a network of five seaports and two international airports, all within 59km from the park. The ecosystem at Bio-XCell is designed for industrial and healthcare biotechnology with a focus on manufacturing and R&D&C.

About Strides Arcolab Ltd.

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.



About Agila Specialties

Agila Specialties Private Limited is the specialties unit of Strides Arcolab which was spun off as a separate division post the Company's restructuring in 2009. It is focused on key domains such as oncolytics, penems, pencillins, cephalosporins, ophthalmics, peptides and biosimilars and operates from 7 world class global manufacturing facilities, including one of the largest steriles capacity in India and amongst the largest lyophilization (freeze drying) capacities in the world. Agila's marketing network covers 75 countries and it has partnerships with some of the world's leading pharmaceutical companies for both developed and emerging markets.

Additional information is available at the company's website at www.stridesarco.com.

About Bio-XCell

Bio-XCell is a biotechnology ecosystem for industrial and healthcare biotechnology, with a focus on manufacturing and R&D. Developed by Malaysian Bio-XCellSdnBhd, a joint venture company between BiotechCorp and UEMLand, the park is slated to be the new regional biotech hub of Asia. Capitalising on value propositions of both its shareholders, Bio-XCell provides comprehensive infrastructure, services, incentives and benefits to drive the growth for the biotechnology sector.

Strategically located in Nusajaya, Iskandar, Malaysia, the resource-rich state of Johor, Bio-XCell provides global connectivity through the network of five seaports and two international airports, all within 59kms. For information or leasing inquiries, log on to www.bio-xcell.com

For further information, kindly contact:

<u>Bio-XCell</u>	<u>Strides</u>
Anita Daud Charles	V.S. Iyer, CEO – Agila Specialties +918066580111
Head, Corporate Communications	Ajay Singh +918066580813 Kannan N +919845054745 (Investors)
Tel : +603 2116 8508	<u>PR Consultancy</u>
Email : anita.daud@bio-xcell.com	Mahesh Nair, Corporate Voice/Weber Shandwick +91 9880376648 maheshn@corvoshandwick.co.in
	Hiba Kunil +91 98807 26372 hiba@hiba@corvoshandwick.co.in

